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Technological innovations in the last decade significantly 
influenced the diagnostic yield of prenatal cytogenetic test-
ing. This impact mostly depends on the testing resolution 
(Srebniak et al., 2017). In fetuses without ultrasound anoma-
lies at the time of sampling (referred due to advanced mater-
nal age [AMA], abnormal first trimester combined test [ftCT] 
results [with nuchal translucency, NT <3.5 mm], recurrence 
risk for chromosome aberrations), we, as others, previously 
showed that the replacement of karyotyping by microarray 
(in our clinic in 2012) led to a higher yield of pathogenic 
chromosome aberrations (Srebniak et al., 2017; Van Opstal et 
al., 2015; Vogel et al., 2018; Wapner et al., 2012). Moreover, 
our group showed that the majority of pregnant women opted 
for maximal information when applying for invasive testing 
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Background: Two technological innovations in the last decade significantly influ-
enced the diagnostic yield of prenatal cytogenetic testing: genomic microarray al-
lowing high resolution analysis and noninvasive prenatal testing (NIPT) focusing 
on aneuploidy. To anticipate future trends in prenatal screening and diagnosis, we 
evaluated the number of invasive tests in our center and the number of aberrant cases 
diagnosed in the last decade.
Methods: We retrospectively analyzed fetal chromosomal aberrations diagnosed in 
2009–2018 in 8,608 pregnancies without ultrasound anomalies.
Results: The introduction of NIPT as the first-tier test led to a substantial decrease 
in the number of invasive tests and a substantially increased diagnostic yield of ane-
uploidies in the first trimester. However, we have also noted a decreased detection 
of submicroscopic aberrations, since the number of invasive tests substantially de-
creased. We have observed that pregnant women were interested in broader scope of 
prenatal screening and diagnosis than detection of common trisomies.
Conclusion: Since the frequency of syndromic disorders caused by microdeletions/
microduplications is substantial and current routine NIPT and ultrasound investiga-
tions are not able to detect them, we suggest that a noninvasive test with resolution 
comparable to microarrays should be developed, which will also meet patient's needs.
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(Srebniak et al., 2011; van der Steen et al., 2015). In 2014, 
the introduction of genome-wide noninvasive prenatal testing 
(NIPT) in the Netherlands as an alternative for invasive test-
ing in a high risk population (abnormal ftCT >1:200, previ-
ous child with trisomy), led to a decreased diagnostic yield in 
the test population in our region (Srebniak et al., 2017). This 
decrease was mostly caused by an inherent prenatal underde-
tection of submicroscopic aberrations, since the vast majority 
of pregnant women preferred NIPT (with limited resolution 
of ~15–20 Mb) over invasive diagnostic testing (resolution 
~500 kb) (Van Opstal et al., 2015). Concerns on this under-
detection of chromosome aberrations were also noted by 
Evans, Andriole, et al., (2018) and Evans, Evans, Bennett, & 
Wapner, (2018).
We have seen that the noninvasive character of NIPT has a 
tremendous psychological impact on pregnant women. More 
patients with high risk results after ftCT were willing to un-
dergo follow-up investigations after NIPT was introduced 
than when only invasive testing was available. Because after 
introduction of NIPT in high risk pregnancies (with abnormal 
ftCT results) a decrease of diagnostic yield was noticed, we 
have previously concluded that NIPT should not be offered as 
second-tier screening test (Srebniak et al., 2017). Since 2017, 
NIPT as a first-tier screening test is available for every preg-
nant women in the Netherlands in the TRIDENT2 study (van 
der Meij et al., 2019). Following our previous study (Srebniak 
et al., 2017), we also wanted to investigate the effect of this 
major change in the national screening program on the overall 
diagnostic yield in our region, where we routinely offer mi-
croarray for cytogenetic investigations of chorionic villi and 
amniotic fluid. To achieve that, we analyzed the frequency of 
fetal chromosomal aberrations diagnosed in our laboratory in 
the time period 2009–2018 in 8,608 pregnancies. These were 
pregnancies without fetal ultrasound anomalies at the time of 
sampling, that were referred for invasive prenatal microarray 
testing due to AMA, abnormal ftCT (with NT <3.5 mm), re-
currence risk for chromosome aberrations or abnormal NIPT 
results. We evaluated not only the number of aberrant cases, 
but also the number of invasive tests in our center. Such 
evaluations are indispensable to anticipate future trends in 
prenatal screening and diagnosis. The retrospective analysis 
method and exclusion criteria were used as described before 
(Srebniak et al., 2017).
Evaluation of the influence of NIPT as a first-tier screen-
ing test and future perspectives: The introduction of NIPT as 
the first-tier test in our region led to the following.
1. A substantial decrease of the number of invasive tests 
in pregnant women without fetal ultrasound anomalies: 
from 1,176 in 2009 (AMA >35 year or abnormal ftCT), 
to 846 (2015, after introduction of NIPT as a second 
tier test and after abolishment of AMA as indication 
for prenatal diagnosis) and further down to 363 in 2018 
(after introduction of NIPT as a first tier screening) 
(Figure 1).
2. In contrast to the previous study (Srebniak et al., 2017), 
a substantially increased diagnostic yield of pathogenic 
fetal chromosomal aberrations (Figures 1 and 2) in the 
first trimester was noted. The observed increase mainly 
involved the common aneuploidies (Figure 2).
3. However, it was noted that the total number of trisomy 
21 cases diagnosed per year in all tested pregnancies 
(with or without ultrasound anomalies) still did not nota-
bly change, most probably due to the fact that uptake for 
F I G U R E  1  The number of fetuses 
without ultrasound anomalies (at the time 
of sampling) that were referred for invasive 
prenatal testing (amniocentesis or chorionic 
villi biopsy) and the percentage of aberrant 
cases in 2009–2018. The different settings 
are indicated: karyotyping, array, NIPT 
2ndT—NIPT as a second screening test, 
NIPT 1stT—NIPT as a first screening test. 
The introduction of NIPT as a first tier 
screening test led to substantial decrease 
in the number of invasive tests. NIPT, 
noninvasive prenatal testing
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prenatal screening/testing did not increase with the intro-
duction of NIPT.
4. We have noted a further decreased detection of submi-
croscopic aberrations (Figure 2), since the number of 
invasive tests substantially decreased and current NIPT 
resolution in our laboratory is still limited to ~15–20 Mb, 
enabling the detection of microscopically visible chromo-
some aberrations, but missing the submicroscopic ones. 
Moreover, detection is limited to autosomal chromosome 
aberrations.
From this study, we may conclude that the current prena-
tal screening program in the Netherlands is effective for com-
mon trisomies in our region, because it reduces the number of 
invasive testing, increases the efficiency of invasive prenatal 
testing and maintains the diagnostic yield of Down syndrome 
cases. Unfortunately due to limited NIPT resolution, it also 
shows that microdeletions/microduplications to a large ex-
tent will remain undiagnosed prenatally, and we previously 
showed that these disorders are unlikely to be detected by ul-
trasound examination (Srebniak et al., 2018). It is concerning 
as their incidence is rather high: 1:270, which is much higher 
than the prevalence of Down syndrome in younger women 
(Srebniak et al., 2018).
Our research data also showed that pregnant women are 
highly interested in more than screening for common aneu-
ploidies, but are not willing to opt for invasive testing due to 
the risk for a miscarriage (van der Steen, 2019). This is also 
supported by the Dutch TRIDENT 2 study that showed that 
the majority (ca. 80%) of pregnant couples chooses whole 
genome testing instead of targeted testing of the common 
trisomies (van der Meij et al., 2019).
In conclusion, since the frequency of syndromic disorders 
caused by microdeletions/microduplications is substantial 
and because current prenatal screening protocols with NIPT 
focusing on aneuploidies and ultrasound investigations are 
not able to detect them, we suggest that a noninvasive test (ei-
ther cfDNA [Fiorentino et al., 2017] or cell-based [Vossaert 
et al., 2018]) with resolution comparable to microarrays 
should be developed, which will also meet patient's needs.
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